PRKDC and colonic neoplasm: Since the molecular testing of colon tumors for MLH1, and not MSH3 expression, is a clinical standard, they proposed that MLH1 is a much better marker to be assessed for a more significant number of patients to benefit from PRKDC inhibition [93].